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Tick evasins (EVAs) bind either CC- or CXC-chemokines by a
poorly understood promiscuous or “one-to-many” mechanism
to neutralize inflammation. Because EVAs potently inhibit
inflammation in many preclinical models, highlighting their
potential as biological therapeutics for inflammatory diseases,
we sought to further unravel theCXC-chemokine–EVA interac-
tions. Using yeast surface display, we identified and character-
ized 27 novel CXC-chemokine–binding evasins homologous to
EVA3 and defined two functional classes. The first, which
included EVA3, exclusively bound ELR CXC-chemokines,
whereas the second class bound both ELR and ELR CXC-
chemokines, in several cases including CXC-motif chemokine
ligand 10 (CXCL10) but, surprisingly, not CXCL8. The X-ray
crystal structure of EVA3 at a resolution of 1.79 Å revealed a
single antiparallel -sheet with six conserved cysteine residues
forming a disulfide-bonded knottin scaffold that creates a con-
tiguous solvent-accessible surface. Swapping analyses identified
distinct knottin scaffold segments necessary for different CXC-
chemokine–binding activities, implying that differential ligand
positioning, at least in part, plays a role in promiscuous binding.
Swapping segments also transferred chemokine-binding activ-
ity, resulting in a hybrid EVA with dual CXCL10- and CXCL8-
binding activities. The solvent-accessible surfaces of the knottin
scaffold segments have distinctive shape and charge, which we
suggest drives chemokine-binding specificity. These studies
provide structural and mechanistic insight into how CXC-
chemokine–binding tick EVAs achieve class specificity but also
engage in promiscuous binding.
The 45–50 mammalian chemokines are small secreted pro-
teins that are grouped into CC, CXC, XC and CX3C classes
based on the spacing between N-terminal cysteine residues.
Their chemotactic functions are mediated by binding to a fam-
ily ofG-protein coupled receptors. Chemokines are structurally
conserved,with a three-stranded-sheet, an-helical segment,
and an N-terminal unstructured region (1) along with an
N-loop between the second Cys and the 1-strand and 30S and
40S loops between the three -strands. Certain CXC-chemo-
kines, referred to as “ELR,” contain a characteristic Glu-Leu-
Arg motif in the N-terminal region that binds chemokine
receptors CXCR17 andCXCR2 and activates neutrophil migra-
tion (2). Binding of chemokines to receptors occurs via chemo-
kine recognition site 1 (CRS1), located in the extracellular N
terminus of the receptor, and CRS2, located in the seven-trans-
membrane bundle. CRS1 binds the proximal N terminus and
N-loop/40S loop, whereas CRS2 binds the chemokine distal N
terminus (3). The “two-site” model has been refined more
recently with the identification of further interaction sites:
CRS1.5, between CRS1 and 2, which binds the conserved
chemokine disulfide, and CRS0.5, at the receptor distal N ter-
minus, which binds the 1-strand of the chemokine (3). The
binding of chemokines to receptors typically involves promis-
cuous interactions, with several chemokines possessing the
ability to bind multiple receptors and, conversely, several
receptors having the ability to bind multiple chemokines (4).
This phenomenon, togetherwith the expression of a large num-
ber of chemokines at sites of inflammation (5) and the expres-
sion of several synergistically acting chemokine receptors on
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inflammatory cells (6, 7), renders the chemokine network
robust to attack. It explains, at least in part, the failure of tar-
geting individual chemokines or receptors as a therapeutic
strategy for inflammatory disorders (5, 6, 8).
Several parasites and infectious agents overcome the chemo-
kine network and consequent inflammation by producing
structurally unrelated proteins that bind, in a promiscuous
fashion, tomultiple chemokines (8, 9). Viral proteins (9) such as
poxvirus CrmD and viral CC-chemokine inhibitor (vCCI), her-
pesvirus R17 and M3, and papovavirus chemokine-binding
protein (CBP), bind multiple chemokines, typically via either
the proximal N terminus or via the N-loop/40S loop, prevent-
ing binding to CRS1 (3). Ticks draw blood for days to weeks
without eliciting inflammation (10), and investigation of saliva
of the brown dog tick Rhipicephalus sanguineus revealed the
presence of chemokine-binding proteins (11–13). These pro-
teins, referred to as evasins, suppress chemokine-driven
inflammation by binding andneutralizingmultiple chemokines
(14). Tick evasins fall into two structurally and functionally
unrelated classes. Evasins 1 and 4 (EVA1 and EVA4) are homo-
logous, with eight conserved Cys residues, and specifically bind
subsets of CC-chemokines, whereas EVA3 has six Cys residues
and specifically binds a subset of ELR CXC-chemokines.
Structural characterization of the EVA1–CCL3 complex indi-
cates that it binds with 1:1 stoichiometry, with the N terminus
andN-loop of CCL3 binding theN andC termini of EVA1, with
selectivity being determined by the six residues immediately
preceding the N-terminal Cys of CCL3 (15). The mechanism
underlying the ability of tick evasins to bind multiple specific
chemokines in a promiscuous fashion is not understood. Poten-
tial mechanisms include differential ligand positioning (16), i.e.
where different linear segments of the evasin molecule might
bind different chemokines, or conformational structural plas-
ticity (17, 18), where the same linear segment may adopt differ-
ent conformations that enable it to bind different chemokines.
The ability of EVA1, -3, and -4 to potently inhibit inflamma-
tion in a wide range of preclinical models provides proof of
concept for their use as biological therapeutics in human dis-
ease (14) and has stimulated interest in identifying evasin-like
molecules from other tick species. We (19–21) and others (22)
have recently reported the identification and characterization
of several new evasins from diverse tick genera that specifically
bind CC- but not CXC-chemokines. Many of these novel
evasins have, like EVA1/EVA4, eight conserved Cys residues,
and we refer to them as C8 evasins. We have also reported the
identification of an EVA3 homolog, P1156, that, like EVA3,
binds ELR CXC-chemokines (21).
Here, we report the identification and functional character-
ization of 27 novel CXC-chemokine–binding tick evasins. Like
EVA3, these novel evasins have six Cys residues, andwe refer to
them as C6 evasins. We found that the CXC-chemokine–
binding C6 evasins can be grouped by function into two classes.
Class I, which includes the class founder EVA3, binds ELR
CXC-chemokines, including CXCL1 and/or CXCL8, whereas
class II, which is novel, binds a broader range of ELR and
ELR chemokines but, surprisingly, does not bind CXCL8.We
report the X-ray crystal structure of EVA3 and show that it has
a disulfide-bonded knottin scaffold.We found that discrete seg-
ments within the knottin scaffold form a solvent-accessible
contiguous surface and are necessary for specific CXC-
chemokine–binding activities. Our results indicate that pro-
miscuous but specific CXC-chemokine recognition by EVA3
and its homologs is, at least in part, mediated by differential
ligand positioning on the knottin scaffold and that manipula-
tion of this scaffold surface can be used to engineer evasins with
altered properties.
Results
Yeast surface display identifies novel CXC-chemokine–binding
evasins
We identified 119 putative EVA3 homologs (including the
previously reported P1156) by searching publicly available tick
salivary transcriptome libraries using three iterations of
psiBLAST with the EVA3 sequence as described previously
(19–21). 114 of these sequences were from Ixodes ricinus, four
were from Amblyomma cajennense, and one was from Rhipi-
cephalus pulchellus. We cloned cDNAs encoding the mature
protein sequences from all 119 EVA3 homologs (and EVA3
itself) into three different yeast expression shuttle vectors. The
three shuttle vectors were designed to fuse each tick protein
with surface display tags either at the N terminus (AGA2) or at
the C terminus (AGA2 and SAG1) under the control of an
inducible GAL4 promoter. The plasmid library pool was ampli-
fied, transformed into yeast as a pool, and induced to express
library-encoded proteins on the cell surface with galactose. The
pooled yeast library was screened with individual biotinylated
chemokines (CXCL1, -7, -8, -9, -10, -11, and -12) followed by
streptavidin-AF647 as described previously (19–21). Briefly,
labeled yeast cells were sorted by FACS using a sorting gate,
which was determined by FACS analysis of the yeast cells
labeled with streptavidin-AF647 alone to exclude cells that
nonspecifically bound to streptavidin-AF647. Cells recovered
were regrown, sorted oncemore, and thenplated at lowdensity,
allowing individual yeast clones to be picked and retested to
verify binding to the biotinylated chemokine. In these experi-
ments, individual yeast clones were labeled with streptavidin-
AF647 alone (control) and biotinylated chemokine plus
streptavidin-AF647 (Table S1). Inserts from plasmid DNA
extracted from yeast clones that had detectable binding (above
the control threshold; Table S1) were amplified by PCR and
sequenced to identify the evasin. In selected cases, yeast clones
were also compared with control yeast expressing the relevant
surface display tag by FACS (Fig. S1) to confirm binding to the
screening chemokine.
Expressionandpurificationofnovel evasins inmammalian cells
We successfully expressed EVA3 and the 28 putative evasins
identified in the yeast display screen as secreted C-terminal
StrepII:His-tagged proteins from HEK293F mammalian cells
and purified them using nickel affinity followed by size-exclu-
sion chromatography as described previously (19–21). All puri-
fied proteins stained with the periodic acid–Schiff method,
indicating that they were glycosylated. They also migrated at
molecular weights that were larger than expected, consistent
with their predicted and observed glycosylation (Fig. S2).
Knottin scaffold evasins
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EVA3 homologs fall into two distinct classes defined by
chemokine-binding activity
We assayed the binding of EVA3 and all the novel evasins to
CXC- and CC-chemokines using biolayer interferometry as
described previously (19–21). Evasins were bound to a nickel-
coated biosensor probe through the C-terminal His tag. We
initially screened a panel of human CC- and CXC-chemokines
at 300 nM chemokine concentration. None of the evasins bound
to CC-, CX3C-, or XC-chemokines. Several evasins that were
identified by yeast surface display (e.g. those arising from the
CXCL9 screen) did not bind the screening chemokine by bio-
layer interferometry (BLI; Table S1) but bound other CXC-
chemokines in the same assay. A single evasin, P1101, which
was isolated in theCXCL10 screen, did not bind any chemokine
by biolayer interferometry (Fig. S3 and Table S1). The lack of
concordance in these instances between yeast surface display
and biolayer interferometry, which was performed using pro-
teins produced in mammalian cells, could potentially be
explained by known differences in post-translational modifica-
tions such as glycosylation and sialylation between yeast and
mammalian cells.
We next performed titration assays with serial dilutions of
chemokines that bound at 300 nM to determine binding affini-
ties (Figs. 1 and 2). Target residence times calculated from the
off-rate are shown in Fig. S4. These studies identified two func-
tional classes of EVA3 homologs. The 15 members of class I,
which includes EVA3 andP1156, bindELRCXC-chemokines.
The 14 members of class II bind both ELR and ELR CXC-
chemokines (Figs. 1 and 2). All Class I EVA3 homologs bound
CXCL8 barring P1134. The 14 novel class II EVA3homologs, in
addition to their ELR-binding activity, bound to one or more
of the non-ELR chemokines CXCL10, CXCL11, CXCL13,
CXCL12, and CXCL4. Notably, no evasin that bound CXCL8
was found to bind an ELR chemokine. Two closely related
evasins, P1142 and P1126, both from A. cajennense, shared
high-affinity (Kd 10 nM) binding to CXCL10 and low-affinity
binding (Kd  300 nM) to CXCL11. Two other evasins, P942
and P675, from I. ricinus, had the reverse binding specificity,
binding CXCL11 strongly (Kd  20 nM) and CXCL10 weakly
(Kd  100 nM) (Figs. 2 and 3). We also identified several
evasins that bound the homeostatic chemokines CXCL12
and CXCL13. In particular, P1104, from I. ricinus, bound to
CXCL12. The target residence times of the novel evasins
varied from brief (1 min) to10 min, e.g. for the binding of
P1142 to CXCL10, suggesting that in some cases relatively
stable evasin–chemokine complexes could form.
EVA3 homologs contain six conserved Cys residues and are
glycosylated
We aligned the protein sequences of the 27 evasins that were
confirmed by BLI to bind one or more CXC-chemokines with
EVA3 and the previously reported P1156 (Fig. 3). All recovered
evasins had six conserved Cys residues, the arrangement being
CX3CX6,10CX3,6CX1CX10,11C, with subscript numbers indicat-
ing spacing between Cys residues. These proteins shared
between 26 and 50% identity with EVA3, ranged in length from
61 to 104 residues (molecular mass between 6.1 and 11.9 kDa),
exhibited isoelectric points (pI) between 3.69 and 8.51, and typ-
ically had one or more predictedN- andO-linked glycosylation
sites (Table S2). Analysis of residue conservation in the align-
ment (Fig. S5) shows that the N and C termini of these novel
evasins are poorly conserved compared with the central core
region.
X-ray structural analysis of EVA3 reveals a disulfide-bonded
knottin scaffold
As a first step to understanding how EVA3 and its homologs
bind and neutralize different classes of CXC-chemokines, we
determined the X-ray crystal structure of EVA3. EVA3 was
expressed and purified from Escherichia coli and crystallized
readily. The structure was solved essentially by the SIRAS
method (see “Experimental procedures”). The crystal structure
of the nonglycosylated EVA3 contains twomolecules per asym-
metric unit, monomer A (Gly13–Arg66) and monomer B
(Asp12–Asn56) (Fig. 4A). The two monomers are very similar,
and theC of residues 13–56 can be overlaid with a root-mean-
square deviation of 1.0 Å. In both monomers, the initial N-ter-
minal residues and the C-terminal end, comprising the six-his-
tidine tag, are flexible and are not seen in the electron density
maps. Residues Leu57 to the C-terminal Arg66 are not visible in
monomer B and are only visible in monomer A because of an
extensive-sheet interaction of this region of the proteinwith a
symmetry-related monomer. The EVA3 monomer is com-
posed essentially of a single domain containing a large antipar-
allel -sheet composed of residues Phe17–Thr27 (1) and resi-
dues Lys47–Gly55 (3), with residues Phe38–Gly40 forming a
third short additional strand (2) interacting with residues
His49–Tyr51 of 3. Two extensive loop regions, composed of
residues Ser28–Cys37 and Leu41–Lys47 join the two major
-strands, whereas a very short -helix is present at the N-ter-
minal region residues Ala14–Asn16. The short 2 strand, which
interacts with 3, is held in place by a disulfide bridge between
residues Cys26 and Cys39. The first loop, between strands 1
Figure 1. Characterization of ELR chemokine binding using biolayer interferometry. Biolayer interferometry sensorgrams show P1142 binding to
different doses of chemokines CXCL10 (left panel) and CXCL11 (right panel). Plots display wavelength shift (y axis; nm) versus time (x axis; seconds). Solid lines
indicate collected data; dashed lines indicate fitted data.
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and 2, is rigidified by the presence of two other disulfide
bridges between Cys33 and Cys50 and Cys37 and Cys22. The
topology of EVA3 is that of an archetypal knottin cystine knot
(23), with the Cys3–Cys6 disulfide bond (Cys33–Cys50 in EVA3)
traversing the macrocycle created by Cys1–Cys4 (Cys22–Cys37
in EVA3) and Cys2–Cys5 (Cys26–Cys39 in EVA3) disulfide
bonds (Fig. 4B). This was confirmed by examining chain A
using theKNOTER3D tool available in theKNOTTINdatabase
(24) (Fig. S6). The crystal structure also contains a cadmium ion
present in the crystallization solution that binds to the side-
chain oxygen atoms of Glu60, carbonyl oxygen of Leu57, and
carbonyl of Gly36 of the symmetry-related chain A molecule.
The knottin scaffold of EVA3 creates a contiguous solvent-
accessible surface
To understand the mechanism of chemokine recognition by
the two different C6 evasin classes, we focused on P1142 and
EVA3. P1142 binds CXCL10 with high affinity but does not
bind CXCL8, whereas EVA3 binds CXCL8 with high affinity
but does not bind CXCL10 (see Fig. 2). In the absence of a
structure for P1142, we used the EVA3 chain A template to
model full-length P1142 using the program MODELLER (25).
The models (Figs. 4, B and C, and S7) suggested that P1142 has
a disulfide-bonded core structure similar to EVA3.Modeling of
the solvent-accessible surfaces of EVA3 chain A and of the
P1142model indicated that five predicted solvent-exposed seg-
ments, S1 betweenCys1 andCys2, S2 betweenCys2 andCys3, S3
between Cys3 and Cys4, S4 between Cys4 and Cys5, and S5
between Cys5 and Cys6, are created by the disulfide-bonded
knottin scaffold. These segments (referred to as “loops” in the
knottin literature (23)) are predicted to form a contiguous sol-
vent-accessible surface, with the conserved cysteine residues
buried within the core, in both EVA3 and P1142 (Figs. 4,D and
E, and S6). The primary structure of these segments is poorly
conserved between EVA3 and P1142 (Fig. 4C).
Distinct knottin scaffold segments bind different
CXC-chemokines
To explore the role of the predicted solvent-exposed surface
created by the disulfide-bonded scaffold, we constructed and
produced hybrid proteins that swapped one or more of the sol-
vent-exposed segments between EVA3 and P1142 (Fig. 5,A and
B). These hybrid proteins were expressed in the mammalian
expression system as described above (Fig. S8). First, the small
S3 segment in EVA3 was replaced with the equivalent segment
in P1142 (construct EVA3:S3) and vice versa (construct P1142:
S3). The S3 variants displayed similar binding affinities to
CXCL8 or CXCL10 as the parental evasins (Fig. 5B), showing
that the S3 segment does not confer specificity in binding to
CXCL8 or CXCL10. However, it does appear to be required for
Figure 2. Summarydata of chemokinebindingusingbiolayer interferometry. Binding affinities (Kd; M) of immobilized evasins to humanCXC-chemokines
usingbiolayer interferometry are shown.High-affinitybinding is indicatedas shadesofgreen,mediumaffinity is indicatedas yellow, and lowaffinity is indicated
as shades of orange. Chemokines and evasins are arranged by sequence similarity–based phylogeny. Inflammatory chemokines are colored either red (ELR)
or purple (ELR). A dash (–) indicates that binding was not detected at 300 nM chemokine concentration on the cross-binding screen. An asterisk following a
chemokine indicates that it was used for yeast surface display screening. Data for P1156_IXORI were reported previously (21) and are shown for comparison.
Evasin functional classes I and II are indicated; see text for details.
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binding to CXCL4 in P1142. Next, a larger region between Cys2
and Cys5, containing segments S2, S3, and S4, was swapped
between the evasins (S2–S4 variants). P1142:S2–S4 lost
CXCL10, CXCL2, CXCL1, and CXCL7 binding, indicating that
S2-S3-S4 was required for binding to these chemokines. There
was a reduction in binding toCXCL5 and -6, indicating that this
region in P1142 was necessary for binding these chemokines
and that the equivalent region of EVA3 could not substitute.
EVA3:S2–S4 displayed a marked reduction in affinity toward
CXCL8 compared with EVA3 or EVA3:S3. The reduction in
binding affinity suggests that the S2 and S4 segments of
EVA3 contribute to the interaction with CXCL8. In addition,
there was a loss of binding to CXCL2 and -3, indicating that
S2 and S4 segments were required for binding to these
chemokines and could not be substituted by the equivalent
segments of P1142.
All five segments (S1–S5) were next swapped between the
evasins (S1–S5 variants). Notably, CXCL10 binding was now
Figure 3. Analysis of CXC-chemokine–binding evasins. MUSCLE alignment of CXC-chemokine–binding evasins identified by yeast surface display with
EVA3 (EVA3_RHISA) is shown. The gray bar indicates the conserved disulfide-bonded central core. Bars indicating segments S1–S5 between Cys residues are
colored as magenta, blue, green, yellow, and orange, respectively. Sequences are arranged by sequence similarity–based phylogeny. The protein sequence
prefix indicates the identity, and the suffix indicate the tick species as follows: RHISA, R. sanguineus; AMBCA, A. cajennense; IXORI, I. ricinus. Amino acid residues
are color-coded by physicochemical properties: yellow, aromatic (Phe, Trp, and Tyr); red, acidic (Asp and Glu); blue, basic (Arg, His, and Lys); orange, nonpolar
aliphatic (Ala, Gly, Ile, Leu, Met, Pro, and Val); green, polar neutral (Cys, Asn, Gln, Thr, and Ser). Evasin functional classes I and II are indicated; see text for details.
Knottin scaffold evasins
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partially transferred to EVA3:S1–S5, and CXCL8 binding was
lost (Figs. 5B and S8). Taken together with the P1142:S2–S4
result above, this indicates that a likely binding site for CXCL10
lies either in the S5 and/or in the S1 segment of P1142, in addi-
tion to S2/S4. Likewise, it indicates that binding sites for
CXCL8 lie either in the S5 and/or in the S1 segment of EVA3, in
addition to the S2 and S4 segments identified above.Nobinding
constants could be determined for the chemokine interactions
of P1142:S1–S5. This may in part be due to the predicted intro-
duction of a nonnativeN-linked glycosylation motif at position
Asn24 that may interfere with protein–protein interactions or
protein folding (Fig. 5A). Taken together, the analysis of the
hybrid proteins suggests that the S1 and S5 segments of the
disulfide-bonded scaffold confer specificity in CXCL8/
CXCL10 binding, whereas S2 and S4 segments are also needed
for binding. Moreover, they indicate that certain chemokines
(i.e. CXCL1, CXCL2, CXCL3, CXCL5, and CXCL6) also likely
bind to the parental evasins by distinctive mechanisms medi-
Figure4.X-ray crystal structureof EVA3andmodelofP1142.A, left panel, ribbon structureof EVA3dimer. ChainA is colored red (-helix), yellow (-strands),
and green (loops). Chain B is indicated as gray. Right panel, ribbon structure of EVA3 chain A rotated through 90° about the y axis with the three -sheets
indicated. Orthogonal x, y, and z axes are indicated as red, green, and blue, respectively. B, EVA3 chain A (left) and P1142 homology model (right) showing
disulfide bonds between Cys1 and Cys4 and between Cys2 and Cys5 (gray) that form a macrocycle between segment S1 (magenta) and S4 (yellow) and the
Cys3–Cys6 disulfide bond (cyan) that passes through themacrocycle. Segments S2, S3, and S5 are colored blue, green, and orange, respectively. For clarity, the
main chain is shownas a tube. Orthogonal x, y, and z axes are indicated as red,green, andblue, respectively.C,MUSCLE alignment of EVA3andP1142. Secondary
structures in EVA3 chain A are indicated above the EVA3 sequence and are colored as a red bar (-helix), yellow arrow (-strands), and green line (loop). The
dashed green line indicates residues that are not visible in the EVA3 chain A or chain B X-ray crystal structures. Disulfide bonds between Cys1 and Cys4 and
betweenCys2 andCys5 are indicated ingray, and that betweenCys3 andCys6 is in cyan. Thegray bar indicates the conserveddisulfidebonded central core.Bars
indicating segments S1–S5 are colored as above. Amino acid residues are color-coded by physicochemical properties: yellow, aromatic (Phe, Trp, and Tyr); red,
acidic (AspandGlu);blue, basic (Arg,His, andLys);orange, nonpolar aliphatic (Ala, Gly, Ile, Leu,Met, Pro, andVal);green, polar neutral (Cys, Asn,Gln, Thr, andSer).
D, solvent-accessible surface of EVA3 is shown in two orientations with segments S1–S5 colored on the surface as above. Orthogonal x, y, and z axes are
indicated as red, green, and blue, respectively. E, solvent-accessible surface of P1142 homology model is shown in two orientations with segments S1–S5
colored on the surface as above. Orthogonal x, y, and z axes are indicated as red, green, and blue, respectively.
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ated by segments of the disulfide-bonded scaffold, as binding is
lost or reduced in the hybrid evasins.
To further dissect the mechanism of binding, segments
S2 and S5 or S5 alone was swapped between the evasins
(S2S5 and S5 variants). Intriguingly, the EVA3:S2S5 and
EVA3:S5 variant displayed binding to both CXCL8 and
CXCL10 (Figs. 5B and S8). Binding affinities could not be
determined for P1142:S2S5 or P1142:S5. The reason is
unclear but may in part be due to effects that may interfere
with protein–protein interactions or protein folding. The
Figure 5. Analysis of chemokine binding by EVA3 and P1142. A, CLUSTAL alignment of EVA3 and P1142 hybrids. Amino acid residues identical to EVA3 are
color-coded by physicochemical properties: yellow, aromatic (Phe, Trp, and Tyr); red, acidic (Asp and Glu); blue, basic (Arg, His, and Lys); orange, nonpolar
aliphatic (Ala, Gly, Ile, Leu,Met, Pro, andVal);green, polar neutral (Cys, Asn,Gln, Thr, andSer). DisulfidebondsbetweenCys1 andCys4 andbetweenCys2 andCys5
are indicated in gray, and that between Cys3 and Cys6 is in cyan. The gray bar indicates the disulfide-bonded central core. The intercysteine segments are
indicatedby colored bars:magenta (S1),blue (S2),green (S3),black (S4), andorange (S5).Red andblack boxes around residues indicate predictedO-glycosylation
and N-glycosylation sites, respectively. B, binding affinities (Kd; M) of immobilized parental evasins and hybrids to human CXC-chemokines using biolayer
interferometry. High-affinity binding is indicated as shades of green, medium affinity is indicated as yellow, and low affinity is indicated as shades of orange.
Inflammatory chemokines are colored either red (ELR) or purple (ELR). A dash (–) indicates that a binding constant could not be calculated. Data in italics
indicate results where only four data points could be fitted. C, binding affinities (Kd; M) of immobilized parental evasins and hybrids to humanCXC-chemokines
using biolayer interferometry. BLI was performed as described under “Experimental procedures” except that seven chemokine doses ranging from1000 to 0.8
nM were used. High-affinity binding is indicated as shades of green, medium affinity is indicated as yellow, and low affinity is indicated as shades of orange.
Inflammatory chemokines are colored either red (ELR) or purple (ELR). A dash (–) indicates that a binding constant could not be calculated and is interpreted
as lack of binding.D, neutralization of human CXCL10-induced T-lymphocytemigration. The left panel shows a representative experiment of CXCL10-induced
T-lymphocytemigrationbyEVA3:S5, P1142, andEVA3, respectively. The yaxis shows cell countof T-cellsmigrating through to thebottomchamber in response
to an EC80 dose of CXCL10. Data are shown as mean S.E. of three technical replicates. The x axis shows evasin concentration (log10 molar). IC50 values (M)
indicated in each figurewere estimatedby fitting anagonist-response curvewith four parameters. The right panel shows individual IC50 values andmean S.E.
of five biological replicates. Mean IC50 for EVA3:S5 is 3.11  10
8
M, whereas that for WT P1142 is 1.85  109 M. No inhibition by EVA3 was observed. E,
neutralization of humanCXCL8-inducedgranulocytemigration. The left panel shows a representative experiment of CXCL8-inducedgranulocytemigration by
EVA3:S5, EVA3, and P1142, respectively. The y axis shows cell count of granulocytes migrating through to the bottom chamber in response to an EC80 dose of
CXCL8. Data are shown asmean S.E. of three technical replicates. The x axis shows evasin concentration (log10molar). IC50 values (M) indicated in each figure
were estimated by fitting an agonist-response curve with four parameters. The right panel shows individual IC50 values and mean  S.E. of four biological
replicates. Mean IC50 for EVA3:S5 is 3.23 10
8
M, whereas that for WT EVA3 is 1.94 109 M. No inhibition by P1142 was observed. Error bars represent S.E.
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dual CXCL8- and CXCL10-binding properties of EVA3:S5
were confirmed by conducting BLI experiments in parallel
with EVA3 and P1142 using a wider concentration range of
chemokine (Figs. 5C and S8).
We next examined the ability of EVA3:S5 to neutralize
CXCL10 andCXCL8.We found that EVA3:S5would neutralize
the ability of CXCL10 to recruit activated T-cells, whereas
EVA3 was unable to do so (Fig. 5D). EVA3:S5 retained the abil-
ity to inhibit CXCL8-mediated granulocyte recruitment (Fig.
5E), consistent with the BLI data. These experiments indicate
that the 11 amino acids comprising the S5 segment of P1142
confer specificity in CXCL10 binding and neutralization that
can be transferred to EVA3.
Differences in shape and charge potentially explain distinctive
binding activities
Taken together, the above studies identified three segments
of the P1142 and EVA3 disulfide-bonded scaffold that likely
play an important role in CXC-chemokine binding. These are
(a) the S5 region of P1142, which can be transplanted to EVA3,
conferring ability to bind CXCL10 and CXCL11; (b) the P1142
S2-S3-S4 region, which is important for binding CXCL10,
CXCL2, CXCL1, CXCL4, and CXCL7 as it cannot be substi-
tuted by the equivalent region of EVA3; and (c) the S1 region of
EVA3, which is necessary for CXCL8 binding as swaps where
this is replaced by the P1142 S1 region no longer bind CXCL8.
Complementarity in surface shape and charge play important
roles in directing the specificity of protein–protein interactions
(26, 27). Analysis of solvent-accessible surface shapes of the
above regions in aligned models of EVA3 and P1142 indicates
substantial differences between the shapes of S5 (Fig. 6A), S1
(Fig. 6B), and S2-S3-S4 (Fig. 6C). Analysis of the surface charge
of EVA3 and P1142 solvent-accessible surfaces (Fig. 7,A and B)
indicates that the S5 and S1 segments in P1142 are negatively
charged, whereas the corresponding segments of EVA3 are
positively charged. The positive charge in EVA3 is contributed
by lysine residues, and the negative charge in P1142 is contrib-
uted by aspartate and glutamate residues. Analysis of the S5
segment in all CXCL8-binding evasins shows that there is a
cluster of positively charged lysine or arginine residues (see Fig.
3). Conversely, the S5 and/or S1 segments contains negatively
charged aspartate or glutamate residues in all CXCL10-binding
evasins (see Fig. 3). Taken together, these results suggest that
the differences in shape and charge likely contribute to the
binding of CXCL8 andCXCL10 by EVA3 and by P1142, respec-
tively, and, by extension, to the two different C6 evasin classes.
Discussion
The major findings that emerge from these studies are, first,
the discovery and characterization of novel EVA3 homologs
that bind specific CXC-chemokines in a promiscuous fashion
and, second, the identification of two functional classes of
EVA3 homologs that bind either only ELR or both ELR and
ELR chemokines. This includes in some cases the ability to
bind CXCL10, a major player in Th1-mediated immunity.
Finally, we report the first X-ray crystal structure of the CXC-
chemokine–binding evasin EVA3 and the discovery of a novel
disulfide-bonded knottin scaffold that underlies the remarkable
ability of EVA3homologs to engage in promiscuous but specific
CXC-chemokine binding.
Using yeast surface display, to date, we have identified,
including the previously reported P1156 (21), 28 novel CXC-
chemokine–binding proteins that share a six-cysteine-residue
architecture resembling EVA3. These EVA3-like proteins have
been confirmed to bind CXC-chemokines following purifica-
tion in mammalian expression systems. Notably, only a subset
of CXC-chemokines was used in the yeast surface display
screens, and it is possible that yet more CXC-chemokine–
binding evasins exist. Remarkably, 26 of these CXC-
chemokine–binding evasins are from the castor bean tick I. ric-
inus, and only two from the Cayenne tick A. cajennense. This
bias most likely reflects the original population of the yeast
surface display library, which consisted predominantly of I. ric-
inus sequences. Our unpublished psiBLAST analysis of the
I. ricinus salivary transcriptome identified 147 putative evasin
homologs of which 114 were putative EVA3 homologs, pre-
dicted to bind CXC-chemokines; the rest were putative EVA4/
EVA1 homologs that would be predicted to bind CC-chemo-
kines. By comparison, our unpublished analysis of the
A. cajennense salivary transcriptome revealed 72 putative eva-
sin homologs ofwhich 68were EVA4/EVA1homologs and four
were EVA3homologs.Our previous studies have identified sev-
eral CC-chemokine–binding EVA4/EVA1-like evasins from
Amblyomma but none from Ixodes (19–21). This suggests that
I. ricinus and Amblyomma species, which represent prostriate
and metastriate tick lineages, respectively, that diverged 241
million years ago (28), evolved distinctive strategies to target
Figure 6. Shape of P1142 and EVA3 solvent-accessible surfaces. A–C, sol-
vent-accessible surfaces of P1142 and EVA3 highlighting segments S5 (A), S1
(B), S2-S3-S4 (C), respectively. Left panels, P1142 (gray, with indicated segment
in green); middle panels, EVA3 (wheat, with indicated segment in orange), and
right panels, overlaid aligned molecules. In each panel, the orthogonal x, y,
and z axes are indicated as red, green, and blue, respectively.
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the chemokine network. These observations, together with
direct studies of anticytokine activity in tick saliva (29), suggest
that Ixodes predominantly targets CXC-chemokines, whereas
Amblyomma targets both CC- and CXC-chemokines.
Like other evasins (15, 19, 30), these CXC-chemokine–
binding evasins are glycosylatedwhen expressed inmammalian
cells and have several predicted N- and O-linked glycosylation
sites. The glycosylation is consistent with the presence of sev-
eral molecular weight species on size-exclusion chromatogra-
phy and slower migration on electrophoresis. The function of
glycosylation may be to reduce immunogenicity (31, 32) and
enhance protein stability (33). It remains to be shown whether
evasin glycosylation directly affects interactions between all
evasins and chemokines. In the case of EVA1, glycosylated and
deglycosylated versions have similar binding properties, and
the structures of both forms are similar (15). EVA3 was simi-
larly equally active in both forms. However, we have found that
deglycosylated P672 has a substantially reduced affinity for its
target, CCL8 (20).
A clear finding emerging from our analyses is that CXC-
chemokine–binding evasins fall into twodistinct classes.Mem-
bers of the first class, which includes the class founder EVA3,
bind one or more ELR CXC-chemokines, including CXCL1
and/or CXCL8, but not ELR chemokines. Members of the
second class bind both ELR and ELR chemokines but, sur-
prisingly, do not bind CXCL8. Both CXC-chemokine–binding
evasin classes are found in I. ricinus. As a major function of
ELR chemokines is to recruit neutrophils via CXCR1/2 bind-
ing (2), the significance of ELR CXC-chemokine binding, we
suggest, would be to inhibit the early neutrophilic infiltration
that occurs at the site of the tick bite (34). CXCL10 and -11 play
important roles in Th1-mediated immunity (2, 35), and inhibi-
tion of these chemokines by several ELR CXC-chemokine–
binding evasins may mediate, in part, the suppression of Th1
responses observed in tick infestation (34).We observed that
several evasins that display strong binding to CXCL11 only
weakly bind CXCL10 and vice versa. CXCL10 and CXCL11
have been suggested to have opposite activities (36) with
CXCL10 promoting and CXCL11 suppressing T-cell–
mediated autoimmunity. Thus, evasins that preferentially
bind CXCL10 may be useful tools to modulate T-cell–
mediated autoimmunity.
Our X-ray crystallographic and homology modeling studies
indicate that EVA3 and its homologs have a topology referred
to as a cystine knot (23) and belong to the class of proteins
known as knottins. The disulfide-bonding pattern (but not the
cystine knot topology) of EVA3 was recently predicted using
selenocysteine scanning (37), and our X-ray crystallographic
analyses are consistent with this previous report. Knottins form
the largest inhibitor cystine-knot subgroup and are character-
ized by the knot-forming disulfide bond betweenCys3 andCys6
traversing a macrocycle created by disulfide bonds between
Cys1 and Cys4 and between Cys2 and Cys5. Other subgroups of
inhibitor cystine knots are cyclotides, where the backbone is
also cyclized, and growth factor cystine knots, which have a
different topology. Knottins are widely found in eukaryotes,
with molecular activities ranging from ion channel blockade to
protease inhibition. The cystine-knot structure provides a high
degree of stability, maintaining both structure and function fol-
lowing exposure to proteolytic enzymes, pH change, and tem-
perature variation, potentially allowing oral delivery (23, 38).
The chemical diversity created from variation in the loop seg-
ments that mediate protein interactions and the ability to read-
ily engineer the loop segments render these molecules attrac-
tive for development as therapeutic and diagnostic agents (23,
38). Knottins already approved for therapeutic use include lina-
clotide (Linzess) and ziconotide (Prialt). Searches of the
online KNOTTIN database (24) suggest that EVA3 and its ho-
mologs represent the first structurally documented knottin
family isolated from ticks and the first description of knottins
that target chemokines, extending the therapeutic potential of
the knottin family.
Taken together with the previous report on the structure of
EVA1 (15), these results indicate that ticks produce two struc-
turally unrelated chemokine-binding protein classes that each
contain novel structural elements. Ticks are arthropods of the
subphylum Chelicerata, and importantly, other chelicerate
arthropods, spiders and scorpions, have several knottin pep-
tides as venom constituents (39), suggesting that EVA3-like
evasinsmay have originated in the ancestral chelicerate.Molec-
ular analysis indicates that ticks diverged frommites336mil-
lion years ago, soon after the appearance of amphibians (28),
whichmay represent the first hosts of ticks (40). CC- and CXC-
chemokines are present in amphibians, reptiles, birds, and
mammals (41). The appearance of CC- and CXC-chemokine–
binding evasins in ticks, which parasitize these vertebrates (40),
likely represents an evolutionary adaptation to neutralizing
Figure7. ChargeofP1142andEVA3solvent-accessible surfaces.A, 3D structuralmodels of P1142 (left) andEVA3 (right) showing solvent-accessible surface
with surface electrostatic potential indicated as red (negative charge) and blue (positive charge). The S5 segment is indicated. B, 3D structuralmodels of P1142
(left) and EVA3 (right) with surface electrostatic potential displayed as above, showing the S1 segment. Orthogonal x, y, and z axes are indicated as red, green,
and blue, respectively.
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host inflammatory responses, allowing prolonged periods of
blood sucking.
Several class I and class II CXC-chemokine–binding evasins
possess the remarkable ability to bindmultiple specific chemo-
kines in a promiscuous fashion. The mechanisms underlying
this are not understood but may include differential ligand
positioning (16), i.e.where different linear segments of the eva-
sin molecule bind different chemokines, or conformational
structural plasticity (17, 18), where the same linear segment
adopts different conformations that enable it to bind different
chemokines. To investigate this further, we attempted to crys-
tallize EVA3 in complex with a target chemokine, CXCL8.
Unfortunately, although EVA3 could be readily crystallized,
cocrystals with CXCL8 could not be obtained. Comparison
with the structure of EVA1 indicated that there is no similarity
between the two tick evasin classes (15). Thus, there was no
opportunity to use the EVA1–CCL3 cocrystal structure as a
template tomodel the interaction of EVA3or its homologswith
target CXC-chemokines. We therefore exploited the clear dif-
ference in CXCL8- and CXCL10-chemokine binding between
EVA3, which binds CXCL8 but not CXCL10, and P1142, which
binds CXCL10 but not CXCL8, to explore the binding mecha-
nisms using segment-swapping analyses. These experiments
show that discrete solvent-accessible segmentswithin the knot-
tin scaffold surface are important for chemokine binding. Anal-
yses of the surfaces of EVA3 andP1142 suggest that the surfaces
created by these segments differ in shape and in charge, which
potentially explains the different binding characteristics. Nota-
bly, the S5 and/or S1 segment in all CXCL8-binding evasins
have a cluster of positively charged residues, whereas the cor-
responding segments in evasins that bind CXCL10 have nega-
tively charged glutamate or aspartate residues, suggesting that
surface chargemay be an important factor determining binding
specificity. An important caveat to these conclusions is the lim-
ited accuracy of prediction of loop structure by homologymod-
eling programs (42). Key questions that need to be addressed
are whether the segments identified directly bind to target
chemokines independently of the knottin scaffold and the iden-
tity of specific residues that mediate such interactions.
In summary, our studies suggest that the ability of the C6
family of evasin proteins to promiscuously bind multiple spe-
cific CXC-chemokines arises, at least in part, by differential
ligand positioning within the knottin scaffold wherein discrete
segments confer different evasin-binding activities. Our studies
show that manipulation of the evasin knottin scaffold can cre-
ate novel proteinswith altered chemokine-binding specificities,
suggesting the versatility of this scaffold for engineering evasins
with desirable chemokine-binding profiles for therapeutic
application. Taken together, these studies provide structural
and biochemical insight into how CXC-chemokine–binding
tick evasins achieve class specificity but are able to engage in
promiscuous binding. Importantly, understanding themolecu-
lar basis of the promiscuous but specific interactions of the
evasins with target chemokines could allow the development of
novel knottin-based therapeutics with similar promiscuous
mechanisms of action capable of therapeutically tackling com-
plex disease-causing protein-interaction networks.
Experimental procedures
Yeast surface display
A library containing 119 putative 6C tick evasins (and also
EVA3) was constructed by cloning DNA sequences encoding
the mature peptides into yeast surface display plasmids as
described previously (19). Yeast surface display screening was
performed as described previously using biotinylated CXCL8,
CXCL10, CXCL11, and CXCL12 from Almac and biotinylated
CXCL1, CXCL7, and CXCL9 produced in house. Briefly,
EBY100 yeast transformedwith library plasmidswere plated on
solid medium. Colonies were pooled. The pooled library was
grown in liquid culture and induced with galactose to drive
expression of the surface-displayed protein. Yeast were labeled
with biotinylated chemokines and streptavidin-AF647 and then
sorted using FACS. A sorting gate, determined by incubating
yeast library with streptavidin-AF647 alone, was used to
exclude cells nonspecifically binding streptavidin-AF647. The
sorted cells were collected and plated on solid media, and a
second round of sortingwas performed as above. Following this
the cells were plated at low dilution to enable picking of indi-
vidual colonies. Individual yeast colonieswere retested as above
to confirm chemokine binding by FACS. Inserts from plasmids
isolated from individual colonies were then amplified by PCR
and sequenced to identify the cloned evasins.
Plasmids
Expression plasmids were constructed using idempotent
parts using our adaptation of the GoldenGate/GoldenBraid
cloningmethod (19). Yeast plasmids were created in three con-
figurations as described previously (19) with the evasin mature
peptide linked to either N-terminal AGA2_YEAST, C-terminal
AGA2_YEAST, or C-terminal SAG1_YEAST surface display
tags and were driven by a yeast GAL1 promoter. For mamma-
lian expression plasmids, parts included the CAGGS promoter
(from GenBankTM accession number AB281497), Ig signal
peptide (43), StrepII:His tag (GGASAWSHPQFEKLEHHHH-
HHHH, pQE-Trisystem, Qiagen), and bovine growth hormone
terminator (pcDNA3, Invitrogen), and sequences encoding the
evasin mature peptide were identified in the yeast surface dis-
play screen. Following signal peptide cleavage, the expected
sequence at the N terminus is DGG, predicted by SignalP 3.0
(44). For bacterial expression plasmids, parts included a modi-
fied E. coli_lacI:T7:lacO:RBS promoter (from pET28, Nova-
gen), a His12-SUMO tag, an Avitag (45), and E. coli birA (from
Addgene 20856, pDisplay-BirA-ER). The mature peptide
encoding sequences of CXCL1 (Ala35–Asn107), CXCL7 (Ala59–
Asp128), and CXCL9 (Thr23–Thr125) were cloned in-frame fol-
lowing the SUMO tag such that the N terminus would be cor-
rectly created following SUMO protease cleavage. Plasmids,
sequences, and detailed methods of construction are available
on request.
Protein sequence analysis
Sequenceswere alignedusingMUSCLEorCLUSTAL inMega-
lign Pro (DNAStar version 12.3.1, DNAStar Inc.) to construct
alignments and generate sequence similarity–based phylogenetic
trees as described previously (19). The sequence alignment was
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analyzed using plotcon in the EMBOSS suite (46) (http://www.
bioinformatics.nl/emboss-explorer/).8 Glycosylation site predic-
tion was performed using NetNGlyc1.0 (http://www.cbs.dtu.dk/
services/NetNGlyc/)8 and NetOGlyc4.0 (http://www.cbs.dtu.dk/
services/NetOGlyc/)8 (62) as described previously (19). Protein
molecular weight and pI were calculated at ExPASy (http://
web.expasy.org/compute_pi/).8
Evasin production
Evasins (including EVA3) for biolayer interferometry and
cell migration assays were produced in mammalian HEK293F
cells as described previously (19). Transiently transfected
HEK293F cell culture supernatants were loaded on nickel-
charged IMAC Sepharose 6 Fast Flow resin (GE Healthcare)
followed by size-exclusion chromatography. Fractions demon-
strating absorption at 280 nm were analyzed electrophoreti-
cally and pooled for subsequent experiments. Evasin glycosyla-
tion was analyzed by periodic acid–Schiff staining (786-254,
G-Biosciences). EVA3 for crystallization was produced in
E. coli as described below.
Chemokine production
Biotinylated chemokines used for yeast surface display
screening were expressed in E. coli, cleaved with SUMO prote-
ase, and purified as described (20). Briefly, E. coli Roset-
taGamiTM 2 (DE3) cells (Novagen) were transformed with the
relevant expression plasmids and induced with isopropyl
1-thio--D-galactopyranoside, and the soluble fraction isolated
from the cell pellet by sonication and centrifugation was puri-
fied using nickel-charged IMAC Sepharose 6 Fast Flow resin,
eluted, and then treated with SUMO protease (a gift from Dr.
Ritika Sethi). The cleaved protein was purified by cation-ex-
change chromatography on a HiTrap Capto S 1-ml cation-ex-
change column (GE Healthcare) followed by size-exclusion
chromatography.
Biolayer interferometry
Biolayer interferometrywas performed on anOctetRed sys-
tem as described previously (19). Cross-binding against a panel
of human chemokines was performed at 300 nM chemokine
concentration. CCL25, CCL26, and CXCL16, which nonspe-
cifically bound to the sensor, were excluded, as were CXCL17,
CXCL4L1, andXCL2,whichwere not available. To assure func-
tionality of different assay components, biolayer interferometry
experiments were performed such that all chemokines studied
were run in parallel for a given evasin, and several evasins were
run in parallel for the chemokine panel. Binding kinetics were
evaluated using chemokine concentrations ranging from 600 to
0.4 nM (except where indicated in figure legends) and a nonin-
teracting reference protein to allow for nonspecific binding.
ForteBio Data Analysis 9 software was used to process the data
and calculate association (kon), dissociation (koff), and affinity
(Kd) constants.We used all data where the fitR2 was0.96, and
at least five data points were used to calculate the fit. The dis-
sociation half-life or target residence time was calculated as
described (19, 47) from biolayer interferometry off-rates (koff,
s1, as t1⁄2 	 0.693/(koff  60)). For the domain-swap hybrid
evasins (Fig. 6B), due to weaker binding of some of the hybrid
mutants, the fitting criterion was adjusted to R2 0.89, and at
least five concentration data pointswere used to calculate the fit
except for P1142:S3 and P1142:S2-S4 against CXCL11 and
EVA:S2-S4 against CXCL1 and CXCL8,where the Kd fitting
was based on four concentrations.
Cell lines
HEK293F cells were a gift from Nicola Burgess-Brown (Uni-
versity of Oxford). THP-1 cells were purchased from Sigma. A
MycoAlertTM (Lonza) kit was used to confirm freedom from
Mycoplasma contamination. Cells were functionally authenti-
cated by protein production and chemokine-inducedmigration
as appropriate.
Activated human T-cell migration assay
Peripheral blood mononuclear cells were isolated from
human buffy coat by density gradient centrifugation using
LymphoprepTM density gradient medium (STEMCELL Tech-
nologies) and centrifuged in SepMateTM isolation tube (85450,
STEMCELL Technologies). Human T-cells were further iso-
lated using the humanCD8T-cell isolation kit (07801, STEM-
CELL Technologies). The enrichment of CD8 T-cells was
confirmed by labeling cells with CD8-FITC (130-110-667,
Miltenyi Biotec) and CXCR3-APC (130-101-378, Miltenyi Bio-
tec) and analyzed on an Attune NxT flow cytometer. Isolated
T-cells were then activated in ImmunoCultTM-XF T-cell
expansion medium (10982, STEMCELL Technologies) with
CD3/CD28 T-cell activator at 25 l/ml (10991, STEMCELL
Technologies) and supplemented with 30 units/ml recombi-
nant human IL-2 (200-02, PeproTech). During expansion,
T-cells were passaged every 2–3 days in TexMACS medium
(130-097-196, Miltenyi Biotec) with 1% penicillin/streptomy-
cin  30 units/ml human IL-2 and incubated at 37 °C in 5%
CO2. Activated T-cells were used 10 days after initial activation
and for a further 5 days thereafter, while still proliferating, dur-
ing which activated CD8T-cells weremaintained at 0.3 106
cells/ml until use. The homogeneity of CD8 T-cells was con-
firmed by labeling with CD8-FITC and CXCR3-APC at days 7
and 10. Human activated T-cell migration assays were per-
formed using 96-well Transwell migration plates (3-m pore
size; 3385, Corning). Cells were counted on an Attune flow
cytometer using a forward scatter (FSC) versus side scatter
(SSC) dot plot and a previously defined gate setting for acti-
vated CD8 T-cells. Effective concentrations (EC), EC80 and
EC50, for CXCL10 were determined each day (see Fig. S9).
CXCL10 (0–150 nM; PeproTech) in 150 l of RPMI 1640
medium 2 mM L-Glu 0.5% heat-treated fetal bovine serum
(all from Sigma) were placed in the bottom chamber. Cells (6
104 in 50 l of RPMI 1640 medium  2 mM L-Glu  0.5%
heat-treated fetal bovine serum) were placed in the top cham-
ber and incubated at 37 °C in 5% CO2 for 2 h. The migration
plate was shaken at 850 rpm for 10 min, and medium from the
bottom plate was transferred to a U-bottomed 96-well plate.
Cells were counted on an Attune flow cytometer using an FSC
versus SSCdot plot, and datawere analyzed inGraphPad Prism,
8 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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fitting an agonist-response curve with four parameters. IC50
values for EVA3:S5 andP1142were determined using the above
system. CXCL10 (EC80 dose) and EVA3:S5 (0.015–1000 nM
concentration) or P1142 (0.015 nM-150 nM concentration)were
added to the bottom chamber and incubated for 30min at 37 °C
before beginning the cell migration assay. Data (three technical
replicates for each IC50 determination) were analyzed in
GraphPad Prism, fitting an inhibitor-response curve with four
parameters. The mean IC50 from five biological replicates was
then calculated.
Human buffy coat granulocytemigration assay
Human buffy coat sample was collected on the day of exper-
iment. To extract granulocytes, red blood cells were first
depleted using HetaSepTM (07906, STEMCELL Technologies).
All nucleated cells were then collected, and any remaining red
blood cells were lysed using Red Blood Cell Lysis Solution (130-
094-183, Miltenyi Biotec). Human granulocyte migration
assays were performed using 96-well Transwell migration
plates (3-m pore size). Cells were counted on an Attune flow
cytometer using a FSC versus SSC dot plot. EC80 and EC50 for
each chemokine were determined each day for each batch of
cells isolated from the buffy coat in three technical replicates
(see Fig. S9). Chemokines (0–150 nM (PeproTech) in 150 l of
RPMI 1640 medium  2 mM L-Glu  0.5% heat-treated fetal
bovine serum (all fromSigma)were placed in the bottomcham-
ber. Cells (2 105 in 50l of RPMI 1640medium 2mM L-Glu
 0.5% heat-treated fetal bovine serum) were placed in the top
chamber and incubated at 37 °C in 5% CO2 for 1 h. The migra-
tion plate was shaken at 850 rpm for 10 min, andmedium from
the bottomplatewas transferred to aU-bottomed96-well plate.
Cells were counted on an Attune flow cytometer using an FSC
versus SSCdot plot, and datawere analyzed inGraphPad Prism,
fitting an agonist-response curve with four parameters. IC50
values for EVA3:S5 and EVA3were determined using the above
system. CXCL8 (EC80 dose) and EVA3:S5 (0.05–200 nM con-
centration), EVA3 (0.02 nM-100 nM concentration), or P1142
(100 nM) were added to the bottom chamber and incubated for
30 min at 37 °C before beginning the cell migration assay. Data
(three technical replicates for each IC50 determination) were
analyzed in GraphPad Prism, fitting an inhibitor-response
curvewith four parameters. Themean IC50 from four biological
replicates was then calculated.
Crystallization and structure determination of EVA3
EVA3 was expressed from a pET30a expression vector in
E. coli strain BL21(DE3). The protein was purified from the
soluble cytosolic fraction by cation-exchange chromatography
on Fractogel-SO3 in 50 mM sodium acetate, pH 4.5, by a linear
gradient of 0–0.7 M NaCl followed by size-exclusion chroma-
tography on an Superdex 75 16/60 column (GE Healthcare) in
PBS. The purified protein was dialyzed against 50 mM
NH4HCO3, aliquoted, lyophilized, and stored at 20 °C. The
first crystals of evasin 3 produced in E. coli were obtained from
sitting-drop vapor-diffusion screening using assorted incom-
plete factorial screens. Themost suitable crystals of EVA3were
obtained by vapor diffusion by adding 2l of protein solution at
6mg/ml in 50mMTris-HCl, pH8.0, containing 100mMNaCl to
1 l of 100 mM CdCl2 and 2 l of the well solution, which was
composed of 25% PEG 3350 (v/v) and 100mMBis-Tris buffer at
pH 6.5. The crystals were briefly transferred to a solution com-
posed of the well solution supplemented with 15% (v/v) glyc-
erol, and the crystals were frozen at 100 K. The crystals diffract
beyond 1.80 Å at a synchrotron source, belong to the space
group P3121 with unit-cell dimensions of a	 b	 55.09 Å and
c 	 71.04 Å, have a calculated solvent content of 45%, and
were expected to contain two molecules of evasin 3 per asym-
metric unit. Two potential heavy-atom-derivative soaks were
prepared by soaking the crystals for 24 h in well solution sup-
plemented with 1 mM K2PtCl4 or 1 mM AuKCl4. All data sets
were collected at the X06SA-PXI beamline of the Swiss Light
Source (SLS) at the Paul Scherrer Institute (PSI) in Villigen,
Switzerland. Data were indexed and processed using MOS-
FILM (48) and SCALA from the CCP4 package (49). Initial
heavy-atom positions were determined by Patterson methods
using SHELXL (50) and further refined with SHARP (51).
Although all three data sets (native, Pt, and Au) were used for
phasing, only the data from the crystal containing Pt revealed
heavy-atom positions contributing to phasing power, and the
structure was solved essentially by SIRAS methods. Neverthe-
less, the Au data set was important for getting the best phase
estimates and correlation among data sets (including potential
anisomorphism between data sets due to the decrease of 0.5 Å
in the length of the c axis of the soaked crystals), which enabled
the phase extension up to 1.80 Å. The quality of the initial elec-
tron density map was significantly improved by solvent flatten-
ing using SOLOMON(52) through the interface in autoSHARP
(53). The results of the data collection and phasing are summa-
rized in Table S4. The solvent-modified phases produced a
clear and interpretable electron density map, and the initial
model was tracedwithARP-WARP (54) with 45 of 134 residues
being docked to the electron density. The initial model was
improved by visual inspection, and model building was per-
formed with Coot (55). The model was refined to 1.80-Å reso-
lution using CNX (56) andwas finally submitted to a last step of
TLS (translation, libration, screw) refinement using BUSTER
(57) with a final Rwork of 19.3% and Rfree of 21.31 (5% test set)
using the parameter set of Engh and Huber (58). The data pro-
cessing and refinement statistics are summarized in Tables S4
and S5. The coordinates of EVA3 are available from the Protein
Data Bank under accession number 6I31.
Homologymodeling
Homology modeling of P1142 mature peptide sequence
was performed using MODELLER (25) with PYMOD2.0
plugin in PyMOL (59) using the EVA3 chain A structure as
template. Following alignment of P1142 and EVA3 using
MUSCLE, homology modeling was performed using default
parameters, i.e. using all heteroatomic residues, not includ-
ing water molecules or automatically building or creating
disulfides, at default optimization level, and no additional
energy minimization, to build 10 models (Fig. S7). The model
with the lowest discrete optimized protein energy (DOPE)
score was then chosen for further analysis. Solvent-accessible sur-
face and electrostatic potential were modeled using the Adaptive
Poisson-BoltzmannSolver (APBS) plugin inPyMOL2.3 (60) using
Knottin scaffold evasins
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default parameters. Relative surface accessibility was computed
as described (61) at the web server ASAView (http://ccbb.jnu.
ac.in/shandar/servers/asaview/).8
Statistical analyses
GraphPad Prism was used to calculate summary statistics.
Ethics approval
All experiments performed on human samples were carried
out according to the University of Oxford guidelines following
ethics approval (study title, Assays for the development of anti-
inflammatory therapeutics; ethics reference, 18/YH/0144).
Data availability
Data supporting this study are available either here within
the text or as supporting information. The coordinates of EVA3
are available from the Protein Data Bank under accession num-
ber 6I31. For nucleotide accession numbers, see Table S2.
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